Intech Investment Management LLC Sells 16,778 Shares of Scholar Rock Holding Corporation $SRRK

Intech Investment Management LLC reduced its stake in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) by 37.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,513 shares of the company’s stock after selling 16,778 shares during the quarter. Intech Investment Management LLC’s holdings in Scholar Rock were worth $1,062,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. US Bancorp DE boosted its stake in shares of Scholar Rock by 81.6% in the 3rd quarter. US Bancorp DE now owns 2,822 shares of the company’s stock valued at $105,000 after purchasing an additional 1,268 shares in the last quarter. Verus Capital Partners LLC acquired a new stake in shares of Scholar Rock during the 3rd quarter worth about $699,000. Eagle Health Investments LP lifted its holdings in Scholar Rock by 34.9% during the 3rd quarter. Eagle Health Investments LP now owns 363,300 shares of the company’s stock valued at $13,529,000 after purchasing an additional 93,900 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Scholar Rock by 1.1% during the 3rd quarter. Vanguard Group Inc. now owns 4,914,927 shares of the company’s stock valued at $183,032,000 after purchasing an additional 53,333 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in Scholar Rock by 161.0% in the third quarter. JPMorgan Chase & Co. now owns 713,988 shares of the company’s stock valued at $26,589,000 after buying an additional 440,401 shares in the last quarter. 91.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $58.00 price objective on shares of Scholar Rock in a research note on Tuesday, March 3rd. Cantor Fitzgerald reissued an “overweight” rating on shares of Scholar Rock in a report on Thursday, December 11th. JPMorgan Chase & Co. increased their price target on Scholar Rock from $46.00 to $47.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Scholar Rock in a report on Thursday, January 22nd. Finally, UBS Group started coverage on Scholar Rock in a research report on Wednesday, January 7th. They issued a “buy” rating and a $60.00 price objective for the company. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $54.14.

Insider Transactions at Scholar Rock

In other Scholar Rock news, insider Mo Qatanani sold 14,898 shares of the company’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $46.71, for a total transaction of $695,885.58. Following the transaction, the insider owned 85,660 shares of the company’s stock, valued at approximately $4,001,178.60. This represents a 14.82% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Keith Woods sold 16,746 shares of the stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $42.70, for a total value of $715,054.20. Following the completion of the transaction, the chief operating officer owned 583,254 shares in the company, valued at $24,904,945.80. The trade was a 2.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 208,470 shares of company stock worth $9,201,778 over the last ninety days. 13.30% of the stock is currently owned by insiders.

Scholar Rock Trading Down 1.9%

SRRK opened at $45.29 on Friday. Scholar Rock Holding Corporation has a 1-year low of $22.71 and a 1-year high of $49.82. The stock has a market capitalization of $5.20 billion, a PE ratio of -13.20 and a beta of 0.70. The company has a current ratio of 6.95, a quick ratio of 6.30 and a debt-to-equity ratio of 0.41. The firm has a 50-day moving average price of $45.32 and a two-hundred day moving average price of $39.35.

Scholar Rock (NASDAQ:SRRK) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.76) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.10. During the same quarter last year, the business earned ($0.64) EPS. As a group, equities analysts anticipate that Scholar Rock Holding Corporation will post -2.42 earnings per share for the current fiscal year.

Key Headlines Impacting Scholar Rock

Here are the key news stories impacting Scholar Rock this week:

• Positive Sentiment: FDA & commercial progress for apitegromab creates a clear commercial pathway and longer‑term revenue upside, a material catalyst for the stock. Scholar Rock outlines 2026 apitegromab BLA resubmission and commercial launch following FDA progress
• Positive Sentiment: Recent quarterly results beat consensus (EPS of -$0.76 vs. -$0.86) and triggered a large volume spike, evidence of investor interest and potential momentum. Scholar Rock (NASDAQ:SRRK) Sees Large Volume Increase After Strong Earnings
• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $58 price target while raising several medium‑ and long‑term EPS forecasts (FY2027–FY2030), signaling continued analyst conviction in the company’s longer‑term outlook. Scholar Rock (NASDAQ:SRRK) Earns “Buy” Rating from HC Wainwright
• Neutral Sentiment: HC Wainwright made a mix of small upward revisions to several quarterly estimates (Q1–Q3 2026) but these are modest improvements and mostly reflect modeling tweaks rather than changed guidance from the company.
• Negative Sentiment: HC Wainwright lowered FY2026 and Q4‑2026 EPS estimates (Q4 2026 from -$0.64 to -$0.82; FY2026 to -$3.55 from -$3.45), increasing near‑term uncertainty and likely contributing to selling pressure despite the long‑term upgrades.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).